Comparison of a Drug and Placebo in the Prevention of Migraine Headaches
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01122381 |
Recruitment Status :
Terminated
(poor recruitment)
First Posted : May 13, 2010
Results First Posted : August 19, 2015
Last Update Posted : August 19, 2015
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Headache, Migraine | Drug: ethosuximide Other: placebo comparator | Phase 1 Phase 2 |
Chronic and episodic headaches in veteran populations include migraine, transformed migraine, and post-traumatic headache with migrainous features. More and better prophylactic drugs with fewer side effects (such as weight gain) are needed to treat these disabling, refractory conditions which generally have less than a 50% response rate to preventative treatments.
Rare forms of severe familial hemiplegic migraine (FHM) are considered channelopathies and can be caused by mutations in a calcium channel gene. Serotonin is also known to be a critical neurotransmitter in migraine based on the pharmacology of acute and preventative treatments. We previously identified a "migraine" signaling pathway in an invertebrate C. elegans "hemiplegic migraine" model of a mutant calcium channel upstream from transforming growth factor-beta (TGF-beta) and showed that low serotonin levels can be rescued by treatment with the childhood antiepileptic drug ethosuximide (ESX).
Objective: We propose to test our findings from this invertebrate migraine model to determine its relevance to humans in the prevention of episodic migraine.
Primary Aim: Determine whether ethosuximide (ESX) will be significantly more effective than placebo in reducing migraine headache days. We propose a 3 year, double blind, phase 1/2 randomized, 2:1 ESX:placebo controlled parallel trial in episodic migraineurs comparing migraine headache days during the last 4 weeks of treatment to a pre-treatment 4 week baseline.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 5 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Prevention |
Official Title: | Pharmacologic and Genetic Evaluation of a C. Elegans Model for Migraine |
Study Start Date : | December 2011 |
Actual Primary Completion Date : | April 2014 |
Actual Study Completion Date : | April 2014 |

Arm | Intervention/treatment |
---|---|
Experimental: Arm 1-ethosuximide
ethosuximide blinded capsules of 250mg ESX; titration up to 4 capsules qd (expected) or 5 or 6 capsules for efficacy (not to exceed "30mg"/kg/d) vs maximum tolerability
|
Drug: ethosuximide
ethosuximide (ESX)
Other Name: zarontin |
Placebo Comparator: Arm 2-placebo comparator
placebo same size blinded capsules as the 250mg ESX; similar titration up to 4 capsules qd (expected) or 5 or 6 capsules for efficacy (not to exceed "30mg"/kg/d) vs maximum tolerability
|
Other: placebo comparator
placebo |
- Migraine Headache Days Per 4 Week Period Comparing the Last 4 Weeks of Treatment to a 4 Week Pre-treatment Baseline. [ Time Frame: 4 weeks, end of treatment and pre-treatment baseline ]
Compare number of migraine headache days pre and post treatment between the ESX and placebo group.
Study terminated early-no outcome data available. The single subject assigned to study drug did not actually take it according to subsequent review of ESX drug levels.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 65 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Must be a veteran.
- The number of migraine days per 4-week period is to be 4-14 for a period of 3 months prior to screening for entry into the trial.
- Migraine must have been occurring for 6 months preceding entry into the trial and age of onset should be before age 60 years.
- Migraine must be at least moderate severity and interrupt daily activities in some respect at least 3 times per month.
- As long as the veteran can easily distinguish nonmigraine headaches from migraine, there is no limit on the number of non migraine headache days allowed. "Transformed migraine" headaches due to medication over usage will be excluded according to exclusion criteria #4.
- Migraine diagnosis:
Veterans with headache must have migraine categorized using the International Headache Society (I.H.S.) criteria as illustrated below for the two main types with and without aura.
Criteria for migraine without aura (I.H.S. 1.1)
- > 5 attacks
- headache lasting 4-72 hours when untreated or not successfully treated.
-
headache with two of the following characteristics
- unilateral,
- pulsating,
- moderate to severe intensity,
- aggravation by exertion.
-
one of the following occurs with headache
- nausea and/or vomiting
- photophobia and phonophobia
Criteria for migraine with aura (I.H.S. 1.2)
- at least 2 attacks
-
at least three of the following characteristics:
- One or more fully reversible aura symptoms indicating focal cerebral cortical - and/or brain stem dysfunction.
One or more aura symptoms of the following types:
- Homonymous visual disturbance
- Unilateral parenthesis and/or numbness
- Unilateral weakness
-
Aphasia or unclassifiable speech difficulty
- At least one aura symptom develops gradually over more than 4 minutes or, 2 or more symptoms occur in succession.
- No aura symptom lasts more than 60 minutes. If more than one aura symptom is present, accepted duration is proportionally increased.
- Headache follows aura with a free interval of less than 60 minutes. (It may also begin before or simultaneously with the aura). Headache, nausea and/or photophobia usually follow neurological aura symptoms directly or after a free interval of less than an hour. The headache usually lasts 4-72 hours, but may be completely absent (1.2.5, acephalgic migraine).
Exclusion Criteria:
- Veterans with migraine plus other systemic disorder will be excluded if migraine onset was temporally related to onset of the systemic disorder.
- Blood pressure elevations (must be < borderline values 135/85 for 4 weeks before enrollment into the study). Current treatment for hypertension with beta-blockers, calcium channel blockers, or ace inhibitors not allowed.
- Use of other prophylactic migraine drugs (requires a washout phase) and cannot have failed more than two other prophylactic drugs for migraine.
- Excessive use of acute pain medicines, including narcotics (>10 days month). Those using non-narcotics could be tapered off over 4-8 weeks.
- Receiving disability or seeking disability for headache or chronic pain.
- Significant neck pain or cervicogenic contributors to chronic headache.
- Significant depression, anxiety, post-traumatic stress disorder, or other disabling psychiatric condition.
- Known allergies or serious side effects with ESX or succinimides in the past.
- Known liver or significant renal disease.
- Women veterans of child-bearing age who do not have adequate birth control.
- Chronic bone marrow suppression.
- Using psychogenic or other sedating maintenance drugs.
- History of porphyria.
- History of cluster headache. 15.History of other CNS disease.
- Age younger than 18 years and greater than 65.
- Women veterans who are breastfeeding.
- Veterans with familial hemiplegic migraine (FHM).
Ongoing exclusions during the study:
- The addition of other migraine prophylactic headache medicines is not allowed. 2. New drugs cannot be added that aggravate headache (nitrates, dipyridamole, niacin).

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01122381
United States, Pennsylvania | |
VA Pittsburgh Health Care System | |
Pittsburgh, Pennsylvania, United States, 15240 |
Principal Investigator: | Kathy L Gardner, MD | VA Pittsburgh Health Care System |
Responsible Party: | US Department of Veterans Affairs |
ClinicalTrials.gov Identifier: | NCT01122381 |
Other Study ID Numbers: |
B5043-R |
First Posted: | May 13, 2010 Key Record Dates |
Results First Posted: | August 19, 2015 |
Last Update Posted: | August 19, 2015 |
Last Verified: | August 2015 |
headache, migraine depression disability evaluation weight gain |
Migraine Disorders Headache Headache Disorders, Primary Headache Disorders Brain Diseases Central Nervous System Diseases |
Nervous System Diseases Pain Neurologic Manifestations Ethosuximide Anticonvulsants |